Blocking Notch pathway by ADAM17 inhibitor ZLDI-8 may sensitize HCC cells to sorafenib in vivo and in vitro by affect crosstalk between the Notch1 and Integrinβ/ILK signaling pathways in HCC in vivo and in vitro.438. The gene discussed is ADAM17; the disease is hepatocellular carcinoma.